Screener
Tango Therapeutics TNGX Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
FAQ
- What is Tango Therapeutics's cumulative cost basis?
- Tango Therapeutics (TNGX) reported cumulative cost basis of $222.13M in Q1 2026.
- How has Tango Therapeutics's cumulative cost basis changed year-over-year?
- Tango Therapeutics's cumulative cost basis increased by 40.5% year-over-year, from $158.1M to $222.13M.
- What is the long-term trend for Tango Therapeutics's cumulative cost basis?
- Over 5 years (2020 to 2025), Tango Therapeutics's cumulative cost basis has grown at a 7.3% compound annual growth rate (CAGR), from $161.92M to $230.64M.
Ask your AI about Tango Therapeutics's cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude